Special Issue

Pluripotent Stem Cell for Novel Drug Discovery

Message from the Guest Editor

The discovery of new drugs for diverse human diseases remains a significant challenge. A poor understanding of human pathology and inadequate representation of human diseases in animals impede the development of therapeutic drugs. Currently, the use of human pluripotent stem cell (hPSC)-based derivatives and disease modeling has revolutionized our drug discovery paradigms. Thus, hPSC-based models define a new pathway to enable the rapid development of effective small molecules or therapies for individual patients. In this Issue, we cover the mechanism of discovery of new drugs and highlight various hPSC platforms, which include 2D-monolayer culture, 3D tissues, and complex organoids, in the modeling of a broad range of diseases for preclinical drug development. We discuss the remaining challenges in the use of the above models and the opportunities in shaping ongoing pharmacological research.

Guest Editor

Dr. Kevin G. Chen

1. Department of Microbiology & Immunology, Georgetown University Medical Center, Washington, DC, USA
2. National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA

Deadline for manuscript submissions

closed (22 April 2025)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/174659

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI